Overall, while most alterations overlapped between primary and metastatic tumors, the enrichment of BRD4 in metastatic disease and KIT in primary tumors suggest potentially meaningful differences in progression that should be confirmed in independent datasets. The gene discussed is KIT; the disease is metastatic neoplasm.